FederalBill C-286First Reading
Bill C-286: An act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act
Sponsor: Corey TochorIntroduced June 16, 2026Last checked August 28, 2026
Read the official text on parl.caOfficial version — LEGISinfo, Parliament of Canada
What this bill does
This bill amends federal drug legislation to allow psilocybin and psilocin (the active compounds in 'magic mushrooms') to be prescribed and used as medical treatments under the existing Narcotic Control Regulations, and ensures that drug submissions for these substances automatically receive priority review status from Health Canada.
Plain-language summary by Legisail.
Business impact
Compliance
This bill primarily affects businesses in the healthcare and pharmaceutical sectors — think clinics offering psychedelic-assisted therapy, licensed producers looking to manufacture or distribute psilocybin-based treatments, and pharmacies that may eventually dispense these substances. Doctors, nurse practitioners, midwives, and other authorized prescribers across Canada would be able to legally prescribe psilocybin and psilocin as part of their day-to-day patient care. Pharmaceutical companies or startups developing psilocybin-based drugs would benefit from an automatic fast-track review process, cutting down the time and uncertainty involved in getting Health Canada approval. Both small clinics and larger biotech or pharma operations stand to be affected, depending on where they sit in the supply and care chain.
Does this apply to you?
Your own business or clients you watch for — tell Legisail what matters and it checks every bill and regulation against it.
Where this bill is
First ReadingJune 16, 2026
Next: Second Reading debate
Legisail watches this for you
Tell Legisail about your business and it checks every new bill and regulation against it — you only hear about the ones that matter.
Create a free accountFree · 30 seconds · No credit card